ReviewReproductive biology and endocrinology : RB&E2025
Roles of exosomes in microenvironment-related premature ovarian insufficiency: mechanisms and therapeutic intervention.
Review in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Exosomes are nanoscale vesicles that traffic bioactive cargo and modulate cell-cell communication within the ovarian niche. They are pivotal mediators in ovarian microenvironment-related premature ovarian insufficiency (omePOI): pathogenic exosomes propagate injury, whereas therapeutic Exosomes restore homeostasis to shape the niche and influence disease onset and course. However, omePOI still lacks sensitive predictive biomarkers and disease-modifying therapies; moreover, the complexity of the ovarian niche-encompassing extracellular matrix, stromal and immune compartments, vasculature, and metabolic-redox balance-poses substantial translational challenges. In this Review, we first summarize the current clinical challenges in diagnosing and managing omePOI. We then focus on reported correlations between exosomal alterations and omePOI, and postulate mechanisms by which these vesicles influence disease biology across apoptosis/mitochondrial injury, senescence, inflammation and innate-adaptive crosstalk, angiogenesis, fibrosis/extracellular matrix, and metabolic-redox pathways. Finally, we highlight the potential value of exosomal changes as biomarkers for predicting omePOI and discuss exosomal interventions, including mesenchymal stromal cell-derived and engineered Exosomes, as well as exosome-biomaterial composites together with design principles from ovarian tissue engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.